Osthole Improves Fat Milk-Induced Fatty Liver in Rats: Modulation of Hepatic PPAR-alpha/gamma-Mediated Lipogenic Gene Expression

Abstract

The objectives of this study were to determine the therapeutic effect of osthole, an active constituent isolated from Cnidium monnieri (L.) Cusson (Apiaceae), in hyperlipidemic fatty liver (HFL) rats and investigate the possible mechanism of the osthole treatment. The HFL rat model was established by feeding Sprague-Dawley rats with fat milk for 6 weeks. The experimental rats were then treated with a dose of osthole of 5 - 20 mg/kg for 6 weeks. After the treatment, total cholesterol (TC) and triglycerides (TG) in serum and hepatic tissue, as well as the coefficient of hepatic weight were measured. The results showed that the TC and TG in both serum and hepatic tissue and the coefficient of hepatic weight in the osthole-treated rats were lower as compared to those in the experimental group, respectively (P < 0.05 or P < 0.01). Moreover, as compared to the control group, the osthole treatment increased the PPARα/γ mRNA expression by 58.0 - 84.0 % and 20.4 - 77.4 %, respectively. The related target genes for mRNA expression were also increased by osthole-treatment, e. g., 53.4 - 93.2 % for CYP7A, 21.1 - 63.2 % for L-FABP and 34.1 - 57.3 % for FATP4, while the DGAT mRNA expression was decreased by 26.0 - 44.4 %. The therapeutic effect of osthole was further confirmed by histological evaluation of the liver showing a dramatically decreased lipid accumulation and improved ultrastructure of hepatocytes. In conclusion, osthole exerts therapeutic effects on fat milk-induced fatty liver in rats, by regulating mRNA expression of the target genes of CYP7A, DGAT, L-FABP and FATP4 via increasing the PPARα/γ mRNA expression.

Cnidium monnieri (L.) Cusson - Apiaceae - osthole - fatty liver - PPARα/γ - lipid metabolism

References

• 1 Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance.  Obes Rev. 2004;  5 27-42.
• 2 McCullough A J. Pathophysiology of nonalcoholic steatohepatitis.  J Clin Gastroenterol. 2006;  40 (Suppl 1) S17-29.
• 3 Berger J, Moller D E. The mechanisms of action of PPARs.  Annu Rev Med. 2002;  53 409-35.
• 4 Moller D E. New drug targets for type 2 diabetes and the metabolic syndrome.  Nature. 2001;  414 821-7.
• 5 Jones P S, Savory R, Barratt P, Bell A R, Gray T J, Jenkins N A. et al . Chromosomal localisation, inducibility, tissue-specific expression and strain differences in three murine peroxisome-proliferator-activated-receptor genes.  Eur J Biochem. 1995;  233 219-26.
• 6 Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism.  Endocr Rev. 1999;  20 649-88.
• 7 Lian Q S. Progress in study of chemical constituents and pharmacological effects of the fruit of Cnidium monnieri.  Chin Med Mater. 2003;  26 141-4.
• 8 Song F, Xie M L, Zhu L J, Zhang K P, Xue J, Gu Z L. Experimental study of osthole on treatment of hyperlipidemic and alcoholic fatty liver in animals.  World J Gastroenterol. 2006;  12 4359-63.
• 9 Koteish A, Diehl A M. Animal models of steatosis.  Semin Liver Dis. 2001;  21 89-104.
• 10 Folch J, Lees M, Sloane Stanley G H. A simple method for the isolation and purification of total lipids from animal tissues.  J Biol Chem. 1957;  226 497-509.
• 11 Adams L A, Angulo P. Recent concepts in non-alcoholic fatty liver disease.  Diabet Med. 2005;  22 1129-33.
• 12 Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome.  Curr Opin Lipidol. 2005;  16 421-7.
• 13 Adams L A, Angulo P, Lindor K D. Nonalcoholic fatty liver disease.  Can Med Assoc J. 2005;  172 899-905.
• 14 Reddy J K, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system.  Annu Rev Nutr. 2001;  21 93-230.
• 15 Xu Y, Rito C J, Etgen G J, Ardecky R J, Bean J S, Bensch W R. et al . Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists.  J Med Chem. 2004;  47 2422-5.
• 16 Saad M F, Greco S, Osei K, Lewin A J, Edwards C, Nunez M. et al . Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.  Diabetes Care. 2004;  27 1324-9.
• 17 Farese RV J r, Cases S, Smith S J. Triglyceride synthesis: insights from the cloning of diacylglycerol acyltransferase.  Curr Opin Lipidol. 2000;  11 229-34.
• 18 Post S M, Duez H, Gervois P P, Staels B, Kuipers F, Princen H M. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression.  Arterioscler Thromb Vasc Biol. 2001;  21 1840-5.
• 19 Cheema S K, Agellon L B. The murine and human cholesterol 7alpha-hydroxylase gene promoters are differentially responsive to regulation by fatty acids mediated via peroxisome proliferator-activated receptor alpha.  J Biol Chem. 2000;  275 12 530-6.
• 20 Waterman I J, Zammit V A. Differential effects of fenofibrate or simvastatin treatment of rats on hepatic microsomal overt and latent diacylglycerol acyltransferase activities.  Diabetes. 2002;  51 1708-13.
• 21 Landrier J F, Thomas C, Grober J, Duez H, Percevault F, Souidi M. et al . Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependent.  J Biol Chm. 2004;  279 45 512-8.
• 22 Nanji A A, Dannenberg A J, Jokelainen K, Bass N M. Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation.  J Pharmacol Exp Ther. 2004;  310 417-24.
• 23 Motojima K, Passilly P, Peters J M, Gonzalez F J, Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner.  J Biol Chem. 1998;  273 16 710-4.
• 24 Ameen C, Edvardsson U, Ljungberg A, Asp L, Akerblad P, Tuneld A. et al . Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver.  J Biol Chem. 2005;  280 1224-9.